Osteoporosis

Managing Bisphosphonate Drug Holidays in Patients With Osteoporosis

By

Tori Rodriguez, MA, LPC

Ongoing treatment with bisphosphonate therapy may not be needed to prevent future fractures in certain patients due to the sustained effect of the drug.

Abaloparatide Significantly Reduces Fracture Risk in Women With Postmenopausal Osteoporosis

A meta-analysis showed that abaloparatide treatment reduces the risk for vertebral, nonvertebral, and wrist fractures in postmenopausal women with osteoporosis compared with placebo or other medical treatments.

Outcomes of FRAX-Predicted Risk Treatment Thresholds in Women

Participants included in the study were women aged 40 and older, with a baseline bone mineral density measure after 1996, and with at least a 5-year follow-up.

Ultrasound-Measured Cortical Bone Porosity Linked to Nontraumatic Fracture in Postmenopausal Women

Cortical bidirectional axial transmission measurements may be useful for fracture risk assessment in postmenopausal women.

First Sclerostin Inhibitor Approved for Postmenopausal Women at High Risk for Fracture

The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapies.

Dietary Calcium Intake Unrelated to Postmenopausal Bone Loss in Women With Osteopenia

There is no association between dietary calcium intake and postmenopausal bone loss.

Most Osteoporosis Guidelines Do Not Discuss Patient Choices

Less than 40% of osteoporosis clinical practice guidelines include any mention of patients’ beliefs, values, or preferences.

Osteoporosis Management Inadequate Among Patients With Rheumatoid Arthritis

The prevention of glucocorticoid-induced osteoporosis and postmenopausal osteoporosis is inadequate among patients with rheumatoid arthritis.

Treatments for Preventing Fracture in Postmenopausal Women Compared

Overall, treatments that were associated with the greatest relative risk reduction in fragility fractures included teriparatide, abaloparatide, denosumab, romosozumab and most bisphosphonate.

Managing Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline

Multiple pharmacologic therapies have been shown to reduce fracture rates in postmenopausal women with acceptable safety profiles.

Risk for Diabetes-Related Fracture Varies by Race, Ethnicity

Investigators examined the risk for diabetes-related fracture in a multiethnic population.